Genmab Expands use of IDBS’ ActivityBase Xtended Edition in Hybridoma Discovery
News Sep 12, 2007
IDBS has announced that Genmab BV (Utrecht, The Netherlands) has extended its use of ActivityBase Xtended Edition (ActivityBase XE) within its Hybridoma Discovery department.
Genmab initially purchased ActivityBase XE in 2006 to handle the design, capture, storage and retrieval of their plate-based screening data. Following the implementation, Genmab has more than doubled the number of ActivityBase XE licenses.
With multiple monoclonal antibody products currently in development or under evaluation to treat cancer, inflammatory conditions and infectious diseases, international biotechnology company Genmab sought a data management solution that had the flexibility to handle the data produced from the functional screening of human monoclonal antibody therapies.
ActivityBase XE enables scientists at Genmab to capture, validate and visualize the data from antibody screening in a contextually rich environment.
Arnout Gerritsen, Sr. Manager of Lead Identification at Genmab, commented: “The introduction of ActivityBase XE into our Hybridoma Discovery department has significantly improved the efficiency of our human antibody screening campaigns.
The flexibility inherent within the ActivityBase XE module enables us to use both Excel and non-Excel templates in our analysis.” He added: “Providing a context around the screening results has promoted a better understanding and enhanced decision making.”
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Blood-vessel-on-a-chip Provides Insight into Novel Anti-Inflammatory Drug CandidateNews
Researchers have discovered that synthetic APC-mimicking small molecules called “parmodulins” provide anti-inflammatory and anti-thrombotic protection to endothelial cells on par with APC’s without interfering with normal blood clotting and coagulation, making them attractive new drug candidates.READ MORE